Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737845 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL542776 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL77969 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL13858690 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL9956415 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL25327994 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL7340365 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL11594630 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL625943 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL61394 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1090 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11693314-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-07-04 | — | — | US | claimed |
| CN-109285957-B | Organic light emitting device | 三星显示有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-3679042-B1 | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS | BEIGENE LTD (KY) | 2023-03-01 | — | — | EP | claimed |
| US-11340527-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-05-24 | — | — | US | claimed |
| CN-114315879-A | Double-boron condensed ring compound and organic electroluminescent device comprising same | 江苏三月科技股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-113387931-A | Compound capable of inhibiting or degrading protein kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-09-14 | — | — | CN | claimed |
| CN-111440216-A | Synthesis method of iridium-containing complex | 北京夏禾科技有限公司 | 2020-07-24 | — | — | CN | claimed |
| CN-106938985-A | A kind of 5 amide groups quinolines of alkenyl 8 and its one-pot preparation thereof | 湖南大学 | 2017-07-11 | — | — | CN | claimed |
| EP-2202577-B1 | Chemically amplified positive resist composition and resist patterning process | SHINETSU CHEMICAL CO (JP) | 2014-08-27 | — | — | EP | claimed |
| US-8722321-B2 | Patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | claimed |
| US-20120276485-A1 | PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-11-01 | — | — | US | claimed |
| US-20120270159-A1 | PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-10-25 | — | — | US | claimed |
| EP-1659881-A2 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF | Senomyx Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| EP-1158980-B1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2005041684-A2 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF | SENOMYX INC. (US) | 2005-05-12 | — | — | WO | claimed |
| WO-1999051598-A1 | SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES: SELECTIVE NEUROPEPTIDE y RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-10-14 | — | — | WO | claimed |
| EP-0564406-A1 | Ferrocenyldiphosphine as ligands for homogeneous catalysts | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | claimed |
| US-5206254-A | Antitussive agents | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-04-27 | — | — | US | claimed |
| EP-0361341-A2 | Therapeutics for aids based on inhibitors of HIV protease | MILES INC. (US) | 1990-04-04 | — | — | EP | claimed |
| EP-0179015-A1 | 7-(Aryloxy)-2-naphthoxyalkanecarboxylic acid derivatives, processes for the preparation of these compounds, as well as agents having herbicidal activity containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-04-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11340527-B2 | Resist composition and patterning process | EIF2B1, EIF2B5, WDR1 | KMT2A 1806/4885NISCH 4792/4885CA1 3224/4885 |
| US-11693314-B2 | Resist composition and patterning process | EIF2B1, EIF2B5, EIF2B3 | KMT2A 2222/4885NISCH 4674/4885CA1 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.